Heavily Pretreated, High-Risk Multiple Myeloma

Once weekly selinexor, carfilzomib and dexamethasone was highly active and yielded deep responses in patients with heavily pretreated multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

Allogeneic hematopoietic cell transplantation showed potential in patients with high-risk multiple myeloma, according to findings presented at the ASCO Annual Meeting.

Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, yielded an overall response rate of 97% in 97 heavily pretreated patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.